Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

NCT06511882 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Azacitidine
DRUG: Decitabine
DRUG: Venetoclax

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]